NewTimeSpace News: On 20 August 2026, SG GROUP HLDGS (01657.HK) appointed Ms. Luo Ying, Mr. Chen Liangyin and Mr. Cao Sheng as independent non-executive directors; Ms. Li Limei resigned as executive director; Mr. Zhu Peiqi resigned as company secretary and was succeeded by Ms. Qian Yingying; the three board committees were realigned accordingly.
NewTimeSpace News: On 21 August 2026, DIRECTEL (08337.HK) proposed to reduce the par value of each share from HKD 0.20 to HKD 0.01 and subdivide each authorised unissued share into 20 new shares, with an EGM to be held on 11 September 2026 to consider the proposal; the capital reduction will generate a credit of approximately HKD 46.53 million, which the board currently has no intention to apply against accumulated losses.
August 20, 2026, BCQ(01963.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 8.43 billion, increased by 12.06% YoY
August 20, 2026, YONGHE MEDICAL(02279.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 980.64 million, increased by 13.82% YoY
NewTimeSpace News: On 20 August 2026, CR MEDICAL (01515.HK) appointed Mr. Yu Changjiu as Chief Financial Officer, effective 20 August 2026. Mr. Yu, aged 46, previously served as General Manager of the Financial Management Centre at China Resources Double-Crane Pharmaceutical and Financial Controller of China Resources Health Group, and holds a Master's degree in Engineering from Beihang University and the title of Senior Accountant.
NewTimeSpace News: On 20 August 2026, KAFELAKU COFFEE (01869.HK) announced the disposal of the entire equity of subsidiary Country Sharp to an independent third party for HKD 8,000, constituting a discloseable transaction; the company acknowledged inadvertent oversight in the size test and has implemented compliance remedial measures.
NewTimeSpace News: August 20, 2026, STELLA HOLDINGS(01836.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at USD 786.67 million, increased by 1.5% YoY.
August 20, 2026, CHINA OVS PPT(02669.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 7.48 billion, increased by 4.52% YoY
NewTimeSpace News: August 20, 2026, SHUN TAK HOLD(00242.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at HKD 1.18 billion, decreased by 12.07% YoY.
NewTimeSpace News: August 20, 2026, XXF(02473.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 761.26 million, decreased by 1.03% YoY.
NewTimeSpace News: August 20, 2026, FB MINING(02212.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 64.05 million, increased by 545.29% YoY.
NewTimeSpace News: August 20, 2026, COMBA(02342.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at HKD 2.2 billion, increased by 0.02% YoY.
NewTimeSpace News: On 20 August 2026, CANSINOBIO (06185.HK) announced that its adsorbed tetanus vaccine received NMPA new drug application approval; Phase III data showed antibody GMC at 30 days post-immunization superior to the comparator vaccine, and an exclusive commercialization cooperation has been reached with Grand Life Sciences for Greater China.
NewTimeSpace News: On 20 August 2026, ALLI INTL ED LE (01563.HK) entered into a finance lease agreement to acquire production equipment for RMB 37 million and lease it back for three years, with total rental of approximately RMB 41.075 million at an annual rate of 6.58%, constituting a discloseable transaction.
NewTimeSpace News: On 20 August 2026, HENGRUI PHARMA (01276.HK) disclosed that its subsidiary received the clinical trial approval notice for SHR-7012 injection, indicated for cutaneous lupus erythematosus; no drug targeting the same target has been approved domestically or internationally, with cumulative R&D investment of approximately RMB 25.5 million.
NewTimeSpace News: On 19 August 2026, BROCKMAN MINING (00159.HK) announced that Polaris abandoned its joint venture interest in the Ophthalmia project effective 1 July 2026, leaving the project wholly owned by wholly-owned subsidiary Brockman East, with a book value of approximately AUD 1.128 million.